Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 3-4/2014

01.02.2014 | original article

Evaluation of treatment responses and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic stem cell transplantation: a single-center experience

verfasst von: Wolfgang Füreder, Andrea Paulitsch-Buckingham, Werner Rabitsch, Eva Jäger, Ilse Schwarzinger, Wolfgang R. Sperr, Peter Valent

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 3-4/2014

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

We analyzed the clinical course and outcome in 50 patients (27 males, 23 females) suffering from aplastic anemia (AA), treated in our department between 1987 and 2007. The median age was 37 years (range: 14–70 years). A total of 42 patients received antithymocyte globulin and cyclosporine A (CSA). Seven patients were transplanted using a matched sibling donor upfront, and one patient was treated with CSA and growth factors only. A total of 34 patients (68 %) achieved a complete remission, and 7 (14 %), a partial remission. Eight patients (16 %) did not respond to treatment, and one died shortly after transplantation. Relapses of AA occurred in eight patients (20 %). No obvious correlations between clinical parameters, including age, karyotype, existence of paroxysmal nocturnal hemoglobinuria clones, pretreatment blood counts, progenitor cell counts, and the response to immunosuppressive therapy (IST), were found. We also examined the numbers of colony-forming progenitor cells (CFUs) before and after therapy. In most responding patients, CFU numbers increased substantially after successful therapy. However, even in patients without a substantial increase in CFU, stable remissions were observed. Together, both IST and stem cell transplantation are reasonable treatment options for patients with AA.
Literatur
1.
2.
Zurück zum Zitat Marsh J, Ball S, Cavenagh J. Guidelines for the diagnosis and management of aplastic anaemia. Brit J Haematol. 2009;147:43–70. CrossRef Marsh J, Ball S, Cavenagh J. Guidelines for the diagnosis and management of aplastic anaemia. Brit J Haematol. 2009;147:43–70. CrossRef
3.
Zurück zum Zitat Füreder W, Valent P. Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches. Leuk Lymphoma. 2011;52:1435–45. PubMedCrossRef Füreder W, Valent P. Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches. Leuk Lymphoma. 2011;52:1435–45. PubMedCrossRef
4.
Zurück zum Zitat Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144:206–16. PubMedCrossRef Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144:206–16. PubMedCrossRef
5.
Zurück zum Zitat Song MK, Chung JS, Joo YD, et al. Is the early cyclosporine a level predictive of the outcome of immunosuppressive therapy in severe aplastic anemia? Eur J Haematol. 2009;83:72–8. PubMedCrossRef Song MK, Chung JS, Joo YD, et al. Is the early cyclosporine a level predictive of the outcome of immunosuppressive therapy in severe aplastic anemia? Eur J Haematol. 2009;83:72–8. PubMedCrossRef
6.
Zurück zum Zitat Tichelli A, Socié G, Henry-Amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med. 1999;130:193–201. PubMedCrossRef Tichelli A, Socié G, Henry-Amar M, et al. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med. 1999;130:193–201. PubMedCrossRef
7.
Zurück zum Zitat Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002;99:3129–35. PubMedCrossRef Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002;99:3129–35. PubMedCrossRef
8.
Zurück zum Zitat Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308–14. PubMedCrossRef Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308–14. PubMedCrossRef
9.
Zurück zum Zitat Chang MH, Kim KH, Kim HS, et al. Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia. Eur J Haematol. 2010;84(2):154–9. PubMedCrossRef Chang MH, Kim KH, Kim HS, et al. Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia. Eur J Haematol. 2010;84(2):154–9. PubMedCrossRef
10.
Zurück zum Zitat Führer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106:2102–4. PubMedCrossRef Führer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood. 2005;106:2102–4. PubMedCrossRef
11.
Zurück zum Zitat Bacigalupo A, Podesta M, Raffo MR, et al. Lack of in vitro colony (CFUC) formation and myelosuppressive activity in patients with severe aplastic anemia after autologous hematologic reconstitution. Exp Hematol. 1980;8(6):795–801. PubMed Bacigalupo A, Podesta M, Raffo MR, et al. Lack of in vitro colony (CFUC) formation and myelosuppressive activity in patients with severe aplastic anemia after autologous hematologic reconstitution. Exp Hematol. 1980;8(6):795–801. PubMed
12.
Zurück zum Zitat Podesta M, Piaggio G, Frassoni F, et al. The assessment of the hematopoietic reservoir after immunosuppressive therapy or bone marrow transplantation in severe aplastic anemia. Blood. 1998;91(6):1959–65. PubMed Podesta M, Piaggio G, Frassoni F, et al. The assessment of the hematopoietic reservoir after immunosuppressive therapy or bone marrow transplantation in severe aplastic anemia. Blood. 1998;91(6):1959–65. PubMed
13.
Zurück zum Zitat Podesta M, Piaggio G, Frassoni F, et al. Deficient reconstitution of early progenitors after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19(10):1011–7. PubMedCrossRef Podesta M, Piaggio G, Frassoni F, et al. Deficient reconstitution of early progenitors after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19(10):1011–7. PubMedCrossRef
14.
Zurück zum Zitat Issaragrisil S, U-pratya Y, Yimyam M, et al. Hematopoietic progenitor cells in the blood and bone marrow in various hematologic disorders. Stem Cells. 1998;16 Suppl 1:123–8. PubMed Issaragrisil S, U-pratya Y, Yimyam M, et al. Hematopoietic progenitor cells in the blood and bone marrow in various hematologic disorders. Stem Cells. 1998;16 Suppl 1:123–8. PubMed
15.
Zurück zum Zitat Issaragrisil S, Piankijagum A, Tang-Naitrisorana Y. Abnormalities of hematopoietic progenitor cells in patients with aplastic anemia after hematologic recovery. J Med Assoc Thai. 1989;72(11):643–8. PubMed Issaragrisil S, Piankijagum A, Tang-Naitrisorana Y. Abnormalities of hematopoietic progenitor cells in patients with aplastic anemia after hematologic recovery. J Med Assoc Thai. 1989;72(11):643–8. PubMed
16.
Zurück zum Zitat Matsuo Y, Iwanaga M, Mori H, et al. Recovery of hematopoietic progenitor cells in patients with severe aplastic anemia who obtained good clinical response with a combination therapy of immunosuppressive agents and recombinant human granulocyte colony-stimulating factor. Int J Hematol. 2000;72(1):37–43. PubMed Matsuo Y, Iwanaga M, Mori H, et al. Recovery of hematopoietic progenitor cells in patients with severe aplastic anemia who obtained good clinical response with a combination therapy of immunosuppressive agents and recombinant human granulocyte colony-stimulating factor. Int J Hematol. 2000;72(1):37–43. PubMed
18.
Zurück zum Zitat Geissler K, Hinterberger W, Bettelheim P, Haas O, Lechner K. Colony growth characteristics in chronic myelomonocytic leukaemia. Leuk Res. 1988;12:373–7. PubMedCrossRef Geissler K, Hinterberger W, Bettelheim P, Haas O, Lechner K. Colony growth characteristics in chronic myelomonocytic leukaemia. Leuk Res. 1988;12:373–7. PubMedCrossRef
19.
Zurück zum Zitat Öhler L, Födinger M, Köller M, et al. Interleukin-10 inhibits spontaneous colony-forming unit-granulocyte-macrophage growth from human peripheral blood mononuclear cells by suppression of endogenous granulocyte-macrophage colony stimulating factor release. Blood. 1997;89:1147–53. Öhler L, Födinger M, Köller M, et al. Interleukin-10 inhibits spontaneous colony-forming unit-granulocyte-macrophage growth from human peripheral blood mononuclear cells by suppression of endogenous granulocyte-macrophage colony stimulating factor release. Blood. 1997;89:1147–53.
20.
Zurück zum Zitat Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporine A: 11-year follow up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101:1236–42. PubMedCrossRef Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporine A: 11-year follow up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101:1236–42. PubMedCrossRef
21.
Zurück zum Zitat Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289(9):1130–5. PubMedCrossRef Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289(9):1130–5. PubMedCrossRef
22.
Zurück zum Zitat Maciejewski JP, Kim S, Sloand E, Selleri C, Young NS. Sustained long-term hematologic recovery despite a marked quantitative defect in the stem cell compartment of patients with aplastic anemia after immunosuppressive therapy. Am J Hematol. 2000;65(2):123–31. PubMedCrossRef Maciejewski JP, Kim S, Sloand E, Selleri C, Young NS. Sustained long-term hematologic recovery despite a marked quantitative defect in the stem cell compartment of patients with aplastic anemia after immunosuppressive therapy. Am J Hematol. 2000;65(2):123–31. PubMedCrossRef
23.
Zurück zum Zitat Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Blood. 1996;88(6):1983–91. PubMed Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Blood. 1996;88(6):1983–91. PubMed
24.
Zurück zum Zitat Manz CY, Nissen C, Wodnar-Filipowicz A. Deficiency of CD34 + c-kit + and CD34 + 38- hematopoietic precursors in aplastic anemia after immunosuppressive treatment. Am J Hematol. 1996;52(4):264–74. PubMedCrossRef Manz CY, Nissen C, Wodnar-Filipowicz A. Deficiency of CD34 + c-kit + and CD34 + 38- hematopoietic precursors in aplastic anemia after immunosuppressive treatment. Am J Hematol. 1996;52(4):264–74. PubMedCrossRef
Metadaten
Titel
Evaluation of treatment responses and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic stem cell transplantation: a single-center experience
verfasst von
Wolfgang Füreder
Andrea Paulitsch-Buckingham
Werner Rabitsch
Eva Jäger
Ilse Schwarzinger
Wolfgang R. Sperr
Peter Valent
Publikationsdatum
01.02.2014
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 3-4/2014
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-013-0484-2